Skip to main content

RabMAb® patents

Last edited Mon 22 Nov 2021

Patented technology

Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies.

Our patents cover, inter alia, rabbit fusion partners, rabbit hybridomas, and methods of producing rabbit monoclonal antibodies (US 7,429,487; US 4,292,878; US 7,732,168; US 8,062,867; US 8,367,408; US 9,328,333).